Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.
Why this paper is included
Supporting source evidence:
PFs evaluated**LC typeNo. of studiesSample size rangeIncluded UVA or MVAAboshi, 2014182Japan2012NNYNMR2, 413NSCLC (late)65NSNSAshworth, 2013237UK2012YYPNNarrative1, 2Any (total NS)NSCLC (oligometastatic)49 (23 in analysis of PFs)NS (1064 in analysis of PFs)MVAAshworth, 2014105UK2012YYYNMR1, 2, 320NSCLC (oligometastatic)206 to 262BothBehera, 20165815US2015YNYNMA22NSCLC (I)19 (11 survival)8 to 110NSBerghmans, 20118434Belgium2009NNPNNarrative2Any (> 50)NSCLC (III)3942 to 2048MVABrundage, 20021051Canada2001NNNNNarrative2Any (169)NSCLC88731: 1281MVAButtigliero, 2011494Italy2007YYYYNarrative22mxdC (LC/NSCLC)25 (2 LC)294 to 447MVACarter, 20145362US2010YPNYNarrative2, 412NSCLC (III: IV)54NSMVAChristopoulos, 20135789Greece2013YYNNNarrative21LC174: 56 (NS for 3 studies)NSDeghaidy, 2005923Egypt2004NYNNMA21LC (NSCLC/SCLC)2923 to 1342NSFlorou, 201451Greece2013YNYNNarrative2, 41mxdC NSCLC (early)/SCLC (limited)20 (13 LC; 4 survival only)66 to 2258NSMontazeri, 2009703Iran2008YNYNNarrative21mxdC NSCLC/SCLC104 (26 LC)30 to 651MVANeal, 20158441UK2013YYYYNarrative215mxdC (LC/NSCLC)209 (20 LC)103 to 566NSOlsson, 2009722US2007YYYYNarrative21LC18NS (2 studies with > 1000 pts)BothParsons, 2010695UK2008YYYYMA1, 21LC (NSCLC/SCLC)1061 to 611BothPrades, 20155807Spain2012NYYNNarrative21mxdC LC (LC/NSCLC)51 (3 LC; 1 survival)NSNSSalah, 2012467Jordan2010 (IS)YUYNMR28NSCLC (isolated met)51NS (total 62)BothSlatore, 2010621US2008YPYYNarrative21LC (LC/NSCLC)23 (9 survival)249 to 693,697Bothvon Meyenfeldt, 2012414Netherlands2011YYPNMR23LC19987: 90,088MVAYu, 20155489China2014YUNYMA21NSCLC1021: 412Yes*Where the search dates were not reported, this was based on the latest publication year of included studies (IS)**Three reviews, which evaluated ‘any’ prognostic factor included a minimum of 50 factors: Ashworth, 2013 (237); Berghmans, 2011 (8434); and Brundage, 2002 (1051)REV ID review unique identification number, DB searched more than one reference database searched, No. number, RM used explicit and reproducible methodology used, CH a systematic presentation of the characteristics of included studies presented, QA assessment for the validity of the findings of the included studies conducted, ADC adenocarcinoma, CTX chemotherapy, IS included studies, LC lung cancer, MA meta-analysis, met metastasis, MR meta-regression, MVA multivariate analysis, mxdC mixed cancer, NS not stated, N no, NSCLC non-small cell lung cancer, PF prognostic factor, PR prognostic research, RT radiotherapy, SCC squamous cell carcinoma, SCLC small cell lung cancer, surR surgical resection, sync synchronous, UVA univariate analysis, Y yesModifiable prognostic factors evaluated by included reviewsAuthor, year*REV IDPatient populationPF codeDescriptionStudy designEvaluable studiesSample size rangeSummary measurePooled analysisNarrative synthesis***Patient characteristics Carter, 20145362NSCLC (III: IV)BMILess weight loss or normal BMIRetrospective21NSNS+ in 11 studies;<> in 10 studies Berghmans, 20118434NSCLC (III)BMIBody mass indexNSNSNSNS+ in 1 study;<> NS Berghmans, 20118434NSCLC (III)Weight lossWeight loss (no further details)NSNSNSNS+ in 5 studies;<> NS Brundage, 20021051NSCLC (early)Weight lossNo substantial weight lossNS655: 207NS<> in 6 studies Aboshi, 2014**182NSCLC (late)PSPercentage of patients in study with ECOG PS1 < 60 (vs ≥ 60)Prospective1339: 1217OR<> Berghmans, 20118434NSCLC (III)PSGood performance statusNSNSNSNS+ in 13 studies;<> NS Brundage, 20021051NSCLC (early)PSHigh performance statusNS1369: 408NS+ in 4 studies;<> in 9 studies Carter, 20145362NSCLC (III: IV)PSBetter PS, ECOG 0-1/KPS < 70 (vs ≥ 2, or vs ≥ 80)Retrospective47NSNS+ in 36 studies;<> in 11 studies Berghmans, 20118434NSCLC (III)QoLQuality of life (no further details)NSNSNSNS+ in 1 study;<> NS Montazeri, 2009**703mxdC (LC)QoLPre-treatment (baseline) quality of lifeNS2630: 651NS+ in 24 studies;<> in 2 studies Montazeri, 2009**703mxdC LC (NSCLC)QolPre-treatment (baseline) quality of lifeNS1130: 573NS+ in 10 studies;<> in 1 study Montazeri, 2009**703mxdC LC (SCLC)QolPre-treatment (baseline) quality of lifeNS170NS<> in 1 study Carter, 20145362NSCLC (III: IV)QoLBetter pre-treatment health related QoL/fewer symptomsRetrospective6NSNS+ in 6 studies Berghmans, 20118434NSCLC (III)Smoking statusSmoking (no further details)NSNSNSNS+ in 1 study;<> NS Brundage, 20021051NSCLC (early)Smoking statusSmoking habit (no further details)NS2350: 593NS+ in 2 studies;<> in 21 studies Florou, 2014**51mxdC LC (limited SCLC)Smoking statusNon-smoker: during treatment (vs smoker)Retrospective1215NS+ in 1 study Florou, 2014**51mxdC LC (limited SCLC)Smoking statusEx-smoker: at or after diagnosis (vs current smoker)Prospective1284NS+ in 1 study Florou, 2014**51mxdC LC (early NSCLC)Smoking statusEx-smoker: quit smoking before diagnosis (vs current smoker or never smoked)Prospective1543NS<> in 1 study; Florou, 2014**51mxdC LC (early NSCLC/limited SCLC)Smoking statusNever smoked (vs ex: or current smoker)Prospective2284: 238NS<> in 1 study;+ in 1 study Parsons, 2010695NSCLC (mainly I: IIIA)Smoking statusContinued smoking after diagnosis (vs quit smoking) in NSCLCMixed493: 311HR<> (unadj);− (adj, n=1) Parsons, 2010695SCLC (mainly limited)Smoking statusContinued smoking after diagnosis (vs quit smoking) in SCLCRetrospective270: 611HR− Carter, 20145362NSCLC (III: IV)Smoking statusLess/no smoking statusRetrospective9NSNS+ in 6 studies;<> in 3 studiesHealthcare provider and system Slatore, 2010**621LCInsurance statusMedicaid (vs private, non-Medicaid, or other funded)NS43702: 13,469HR/OR− in 4 studies Slatore, 2010**621LC (NSCLC)Insurance statusCommercial or other insurance (vs private insurance)NS2336: 1403HR/OR<> in 2 studies Slatore, 2010**621LCInsurance statusMedicaid/Medicare (vs Medicare)NS23094: 26,073HR− in 2 studies Slatore, 2010**621LC (NSCLC)Insurance statusMedicaid/Medicare (vs Medicare)NS13,094HR− in 1 study Slatore, 2010**621LCInsurance statusMedicare HMO (vs Medicare Fee for Service)NS110,229HR<> in 1 study Prades, 2015**5807mxdC (NSCLC)MDTMDT patient managementProspective1NSSurvival rate+ in 1 study von Meyenfeldt, 2012**414LCProcedural volumeHigh hospital annual volume of surgical resections (vs low volume): post-operative mortalityNS11 (10 in MR)987 to 90,088OR++ in 6 studies;<> in 5 studies von Meyenfeldt, 2012**414LCProcedural volumeHigh hospital annual volume of surgical resections (vs low volume): overall survivalNS8 (7 in MR)1097 to 40,754HR<>+ in 5 studies;− in 1 study;<> in 2 studies von Meyenfeldt, 2012**414LCProcedural volumeHigh annual surgeon procedural volume (vs low volume): post-operative mortalityNS24841: 24,092HR<>+ in 2 studies von Meyenfeldt, 2012**414LCSurgeonSurgeon specialty: general thoracic surgeon (vs general surgeon): post-operative mortalityNS319,745 to 86,538HR++ in 1 study;<> in 2 studies von Meyenfeldt, 2012**414LCSurgeonSurgeon specialty: general thoracic surgeon (vs general surgeon): overall survivalNS21097: 19,745OR<>+ in 1 study;<> in 1 studies von Meyenfeldt, 2012**414LCSurgeonSurgeon specialty: cardiothoracic surgeon (vs general surgeon): post-operative mortalityNS319,745 to 86,538OR++ in 1 study;<> in 2 studies von Meyenfeldt, 2012**414LCSurgeonSurgeon specialty: cardiothoracic surgeon (vs general surgeon): overall survivalNS21097: 19,745HR+ in 1 study;<> in 1 studies Olsson 2009722LCTimeliness of careShorter intervals to diagnosis or treatmentMixed15NSNS− in 4 studies;<> in 8 studies;+ in 3 studies Neal, 20158441mxdC (LC)Timeliness of careShorter diagnostic interval: time from first seen in primary care to diagnosisMixed4122: 378NS<> in 3 studies;+ in 1 study Neal, 20158441mxdC (NSCLC)Timeliness of careShorter treatment interval: time from first seen in primary care to treatmentRetrospective2415: 495NS<> in 1 study;− in 1 study Neal, 20158441mxdC (NSCLC)Timeliness of careShorter patient interval: time from symptom onset to first seen in primaryRetrospective2122: 7358NS<> in 1 study;− in 1 study Neal, 20158441mxdC (LC)Timeliness of careShorter time from symptom onset to diagnosisRetrospective1NS (total 566)NS+ in 1 study Neal, 20158441mxdC (LC)Timeliness of careShorter time from symptom onset to treatmentRetrospective1NS (total 103)NS<> in 1 study Neal, 20158441mxdC (NSCLC)Timeliness of careShorter time from symptom onset to being seen in specialist careRetrospective1NS (total 415)NS<> in 1 studyClinical characteristics or routinely assessed biological variables Christopoulos, 2013**5789LCTBActive tuberculosis, TB (vs no TB)Retrospective5NSMedian survival− 1 in study;? in 4 studies (no comparative data) Buttigliero, 2011494mxdC LCVitD levelLow serum vitamin D levelProspective2294: 447HR<> in 2 studies Ashworth, 2014**105NSCLC (oligometastatic)StageIB (vs IA)Prospective206: 262HR<> Ashworth, 2014**105NSCLC (oligometastatic)StageIIA (vs IA)Prospective206: 262HR<> Ashworth, 2014**105NSCLC (oligometastatic)StageIIB (vs IA)Prospective206: 262HR− (unadj) Ashworth, 2014**105NSCLC (oligometastatic)StageIIIA (vs IA)Prospective206: 262HR− (unadj) Ashworth, 2014**105NSCLC (oligometastatic)StageIIIB (vs IA)Prospective206: 262HR− (unadj) Ashworth, 2013**237NSCLC (oligometastatic)StageStage I (vs III or IV)Mixed5NSNS+ in 1 studies;<> in 4 studies Aboshi, 2014**182NSCLC (late)StagePercentage of patients in study with stage IV disease < 80 (vs ≥ 80)Prospective1339: 1217OR<> Salah, 2012**467NSCLC (solitary met)StageIntra-thoracic stage III (vs stage II or I)Retrospective36NSHR− Deghaidy 2005**923LC (NSCLC)StageStage I vs II (in NSCLC)Mixed1023: 226RR++ in 5 studies;<> in 5 studies Deghaidy 2005**923LC (SCLC)StageStage I vs II (in SCLC)Mixed424: 295RR++ in 3 studies;<> in 1 study Deghaidy 2005**923LC (NSCLC)StageStage I vs III (in NSCLC)Mixed733: 1342RR++ in 4 studies;<> in 3 studies Deghaidy 2005**923LC (SCLC)StageStage I vs III (in SCLC)Mixed327: 92RR++ in 2 studies;<> in 1 study Deghaidy 2005**923LC (NSCLC)StageStage II vs III (in NSCLC)Mixed757: 961RR++ in 3 studies;<> in 4 studies Deghaidy 2005**923LC (SCLC)StageStage II vs III (in SCLC)Mixed325: 95RR+<> in 3 studies Deghaidy 2005**923LC (NSCLC)StageStage III vs IV (in NSCLC)Mixed621: 2198RR++ in 3 studies;<> in 3 studies Deghaidy 2005**923LC (SCLC)StageStage III vs IV (in SCLC)Mixed222: 319RR<><> in 2 studies Carter, 20145362NSCLC (III: IV)StageLess advanced stage, mainly IIIB (vs IV)Retrospective37NSNS+ in 21 studies;<> in 16 studies Behera, 2016**5815NSCLC (I)StageAdenocarcinoma in situ, AIS (vs minimally invasive adenocarcinoma, MIA)NS118: 110Survival rate<> Berghmans, 20118434NSCLC (III)StageLess advanced stageNSNSNSNS+ in 6 studies;<> NS Brundage, 20021051NSCLC (early)StageLess advanced stageNS10331: 593NS+ in 68 studies;<> in 35 studies Berghmans, 20118434NSCLC (III)T volumeTumour volumeNSNSNSNS+ in 2 studies;<> NS Yu, 2015**5489NSCLC (unresectable)GTVSmall gross tumour volume, GTV < 112 cm3vs (vs large GTV >= 112cm3)NS532: 115HR+Prognostic factors classified as ‘other’ Ashworth, 2014105NSCLC (oligometastatic)Surgical treatmentSurgical primary LC treatment (vs non-surgical)Prospective206: 262HR+ (unadj) Ashworth, 2013237NSCLC (oligometastatic)SurgeryType of thoracic resection: lobectomy (vs pneumonectomy)Mixed2NSNS+ in 1 studies;<> in 1 studies Berghmans, 20118434NSCLC (III)SurgeryR0 (complete resection)NSNSNSNS+ in 4 studies;<> NS Brundage, 20021051NSCLC (early)SurgerySurgical procedure (no further details)NS1543: 593NS+ in 4 studies;<> in 11 studies*Three reviews which evaluated ‘any’ prognostic factor included a minimum of 50 factors: Ashworth, 2013 (237); Berghmans, 2011 (8434); and Brundage, 2002 (1051).
Source: Review of modifiable factors. View original paper
Relevance classification does not establish study quality, causation or editorial approval.
Study design Review / evidence synthesis.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Meta-analysis unclear · Blinding not applicable to this review · Research setting awaiting verification
How this paper was classified
Automatic source-based classification; awaiting editorial verification. This is not a quality score.
Pragmatic methods for reviewing exceptionally large bodies of evidence: systematic mapping review and overview of systematic reviews using lung cancer survival as an exemplar
Source: Article title.
What the study types mean
- Systematic review
- Uses explicit methods to identify, assess and summarise research on a defined question.
- Scoping review
- Maps the extent and characteristics of research on a topic.
- Narrative review
- Discusses existing research; systematic-review methods have not been established by this classification.
- Review / evidence synthesis
- Reviews existing research; the exact review methods need further assessment.
- Randomised controlled trial
- Assigns participants or groups to comparison interventions by chance.
- Non-randomised intervention study
- Examines an intervention without random allocation.
- Cohort study
- Examines exposures and outcomes over time within a defined group.
- Case-control study
- Compares people with an outcome against people without it, examining exposures.
- Cross-sectional study
- Examines a population at a particular point in time.
- Observational study
- Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
- Case report
- Describes an individual case.
- Case series
- Describes a group of individual cases.
- Secondary analysis
- Analyses existing study data; this paper is not automatically another independent trial.
- Laboratory study
- Investigates biological processes in a laboratory setting.
- Qualitative study
- Examines experiences or meanings using qualitative methods.
- Genetic instrumental-variable study
- Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
- Study protocol
- Describes planned methods and is not evidence that the planned study has reported results.
- Multiple reported designs
- More than one design is explicitly reported; examine the supporting methods.
- Study design awaiting verification
- The available source does not establish a sufficiently clear study design.
Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.
Abstracts
Pragmatic methods for reviewing exceptionally large bodies of evidence: systematic mapping review and overview of systematic reviews using lung cancer survival as an exemplar
Review / evidence synthesis · Systematic Reviews · 2019
Original publication title
Pragmatic methods for reviewing exceptionally large bodies of evidence: systematic mapping review and overview of systematic reviews using lung cancer survival as an exemplar
© The Author(s). 2019
Original publication · Publisher record · CC BY 4.0 · CC0
Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.
At a glance
Abstract: What background does the paper provide?
Lung cancer (LC) is the most common cause of cancer death in the world and associated with significant economic burden. We conducted a review of published literature to identify prognostic factors associated with LC survival and determine which may be modifiable and could be targeted to improve outcomes.
Source: IntroductionAbstract: What methods does the paper describe?
The exceptionally large volume of LC prognostic research required a new staged approach to reviewing the literature. This comprised an initial mapping review of existing reviews or meta-analyses, based on titles and abstracts, followed by an overview of systematic reviews evaluating factors that independently contribute to lung cancer survival. The overview of reviews was based on full text papers and incorporated a more in-depth assessment of reviews evaluating modifiable factors.
Source: MethodsAbstract: Electronic supplementary material
The online version of this article (10.1186/s13643-019-1087-4) contains supplementary material, which is available to authorized users.
Source: Electronic supplementary materialAbstract: Results
A large volume of published systematic reviews and meta-analyses were identified, but very few focused on modifiable factors for LC survival. Several modifiable factors were identified, which are potential candidates for targeted interventions aiming to improve cancer outcomes. The mapping review included 398 reviews, of which 207 investigated the independent effect of prognostic factors on lung cancer survival. The most frequently evaluated factors were novel biomarkers (86 biomarkers in 138 reviews). Only 15 modifiable factors were investigated in 20 reviews.
Those associated with significant survival improvement included normal BMI/less weight loss, good performance status, not smoking/quitting after diagnosis, good pre-treatment quality of life, small gross volume tumour, early-stage tumour, lung resection undertaken by a thoracic/cardiothoracic surgeon, care being discussed by a multidisciplinary team, and timeliness of care.
Source: ResultsAbstract: Conclusions
The study utilised a novel approach for reviewing an extensive and complicated body of research evidence. It enabled us to address a broad research question and focus on a specific area of priority. The staged approach ensured the review remained relevant to the stakeholders throughout, whilst maintaining the use of objective and transparent methods. It also provided important information on the needs of future research. However, it required extensive planning, management, and ongoing reviewer training.
Source: ConclusionsAuthors’ abstract
Introduction
Lung cancer (LC) is the most common cause of cancer death in the world and associated with significant economic burden. We conducted a review of published literature to identify prognostic factors associated with LC survival and determine which may be modifiable and could be targeted to improve outcomes.
Methods
The exceptionally large volume of LC prognostic research required a new staged approach to reviewing the literature. This comprised an initial mapping review of existing reviews or meta-analyses, based on titles and abstracts, followed by an overview of systematic reviews evaluating factors that independently contribute to lung cancer survival. The overview of reviews was based on full text papers and incorporated a more in-depth assessment of reviews evaluating modifiable factors.
Results
A large volume of published systematic reviews and meta-analyses were identified, but very few focused on modifiable factors for LC survival. Several modifiable factors were identified, which are potential candidates for targeted interventions aiming to improve cancer outcomes. The mapping review included 398 reviews, of which 207 investigated the independent effect of prognostic factors on lung cancer survival. The most frequently evaluated factors were novel biomarkers (86 biomarkers in 138 reviews). Only 15 modifiable factors were investigated in 20 reviews.
Those associated with significant survival improvement included normal BMI/less weight loss, good performance status, not smoking/quitting after diagnosis, good pre-treatment quality of life, small gross volume tumour, early-stage tumour, lung resection undertaken by a thoracic/cardiothoracic surgeon, care being discussed by a multidisciplinary team, and timeliness of care.
Conclusions
The study utilised a novel approach for reviewing an extensive and complicated body of research evidence. It enabled us to address a broad research question and focus on a specific area of priority. The staged approach ensured the review remained relevant to the stakeholders throughout, whilst maintaining the use of objective and transparent methods. It also provided important information on the needs of future research. However, it required extensive planning, management, and ongoing reviewer training.
Electronic supplementary material
The online version of this article (10.1186/s13643-019-1087-4) contains supplementary material, which is available to authorized users.
Publication and source details
Original title: Pragmatic methods for reviewing exceptionally large bodies of evidence: systematic mapping review and overview of systematic reviews using lung cancer survival as an exemplar
Ruth Lewis; Maggie Hendry; Nafees Din; Marian A. Stanciu; Sadia Nafees; Annie Hendry; Zhi Hao Teoh; Thomas Lloyd; Rachel Parsonage; Richard D. Neal; Gareth Collier; Dyfed W. Huws
Systematic Reviews · 2019
© The Author(s). 2019https://creativecommons.org/licenses/by/4.0/Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.Public Health WalesRepository JATS snapshot; version as supplied
Source retrieved: 2026-11-12T18:28:41.024495+00:00
DOI: 10.1186/s13643-019-1087-4 · PMC6631880